United States Drug Patent 4,017,615: Scope, Claims, and Landscape Analysis

United States Patent 4,017,615, titled "Novel Pyrrolo[2,3-d]pyrimidine Carbonyl Derivatives," issued on June 14, 1977, to the Upjohn Company. The patent claims a class of chemical compounds, specifically pyrrolo[2,3-d]pyrimidine derivatives, and their use as phosphodiesterase (PDE) inhibitors. These compounds are indicated for treating conditions responsive to PDE inhibition, such as asthma and heart failure. The patent's claims are broad, encompassing specific chemical structures and their pharmaceutical compositions.

What are the Key Claims of Patent 4,017,615?

Patent 4,017,615 asserts several key claims pertaining to chemical structure, pharmaceutical formulations, and therapeutic applications.

Chemical Structure Claims

Claim 1 defines the core of the invention:

"A compound of the formula:

     R3
     |
  N--C--R2
 // \\ |
C    N
|    |
R1   C--R4
 \\ //
  N

wherein R1 is hydrogen, alkyl, acyl, carbamyl, or a group of the formula -COOR5 wherein R5 is alkyl or benzyl; R2 is hydrogen or alkyl; R3 is alkyl; and R4 is a nitrogen-containing heterocyclic group selected from the group consisting of piperidino, morpholino, 4-methyl-1-piperazino, 1-piperazino, and 1-homopiperazino; or a pharmaceutically acceptable acid addition salt thereof." [1]

Subsequent claims further refine these structures by specifying ranges for alkyl groups and particular substitutions. For instance, claims detail specific embodiments where R1 is hydrogen, R2 is methyl, and R4 is a particular heterocyclic amine. These claims are crucial as they delineate the specific molecular architectures that fall under the patent's protection. The patent also covers pharmaceutically acceptable acid addition salts of these compounds, which are common in drug formulations to improve solubility and stability.

Pharmaceutical Composition Claims

Beyond the active pharmaceutical ingredients (APIs), the patent claims pharmaceutical compositions.

Claim 10 states:

"A pharmaceutical composition comprising a compound of claim 1 and a non-toxic pharmaceutical carrier." [1]

This claim is significant as it extends protection to the formulated drug product, not just the active molecule. It covers various dosage forms, including oral tablets, capsules, and parenteral solutions, provided they contain a compound from the claimed structural class and a suitable carrier. The inclusion of carrier materials allows for the practical delivery of the API to patients.

Therapeutic Use Claims

The patent also claims the therapeutic applications of these compounds.

Claim 13 asserts:

"A method of treating a condition responsive to phosphodiesterase inhibition which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1." [1]

Conditions explicitly mentioned as responsive to phosphodiesterase inhibition include bronchial asthma and congestive heart failure. This claim provides a legal basis for using the patented compounds in specific medical indications, forming the basis for their commercial development as therapeutic agents.

What is the Scope of the Patent's Claims?

The scope of U.S. Patent 4,017,615 is broad, encompassing a defined class of organic molecules and their medicinal applications. The patent does not claim a single compound but a genus of related structures defined by specific variable substituents (R1, R2, R3, R4) on a core pyrrolo[2,3-d]pyrimidine ring system.

The core structure is a bicyclic aromatic heterocycle. The substitutions at positions R1, R2, R3, and R4 allow for a considerable number of possible chemical entities within the claimed genus. The definition of R4 is particularly important, as it limits the scope to specific nitrogen-containing heterocyclic groups. This specificity ensures that the claims are not overly broad to the point of encompassing known prior art but still cover a substantial chemical space.

The patent’s scope also extends to any pharmaceutically acceptable acid addition salt formed from these compounds. This is a standard practice in pharmaceutical patenting, as salts are often used to improve drug properties.

Furthermore, the inclusion of claims for pharmaceutical compositions broadens the scope to include the final drug product, irrespective of the specific excipients used, as long as a carrier is present. The method-of-use claims further solidify the scope by protecting the application of these compounds for specific therapeutic purposes.

What is the Prior Art Landscape for Pyrrolo[2,3-d]pyrimidine Derivatives?

The patent landscape for pyrrolo[2,3-d]pyrimidine derivatives is extensive, with this core structure appearing in numerous patented compounds and scientific literature, particularly in the context of kinase inhibition and PDE inhibition.

Early Research and Development

Research into pyrrolo[2,3-d]pyrimidines gained momentum in the mid-20th century. Early work focused on their potential as antimetabolites and anticancer agents, drawing parallels with purines due to their structural similarities [2]. Publications in journals like the Journal of the American Chemical Society and Tetrahedron Letters detailed synthetic routes and initial biological evaluations.

Phosphodiesterase Inhibitors

The specific focus of U.S. Patent 4,017,615 is on PDE inhibition. PDE enzymes are crucial regulators of intracellular cyclic nucleotides (cAMP and cGMP), and their inhibition can have various physiological effects, making them targets for treating conditions like asthma, COPD, erectile dysfunction, and cardiovascular diseases.

Prior to 1977, research had identified various chemical classes as PDE inhibitors. For example, xanthine derivatives like theophylline were known PDE inhibitors used for asthma. Research was also progressing on other heterocyclic systems.

Kinase Inhibitors

More recently, the pyrrolo[2,3-d]pyrimidine scaffold has become a prominent feature in kinase inhibitor development, particularly for cancer therapy. Compounds like tofacitinib (a JAK inhibitor) and ruxolitinib (another JAK inhibitor) are well-known examples. These later developments highlight the versatility of the pyrrolo[2,3-d]pyrimidine core, but their mechanisms of action and specific structural modifications differ from those claimed in U.S. Patent 4,017,615. Kinase inhibitors typically target the ATP-binding site of kinases, whereas the compounds in Patent 4,017,615 are directed at PDE inhibition.

Patent Landscape Analysis

A comprehensive patent landscape analysis reveals:

Early Patents: Following the issuance of U.S. Patent 4,017,615, numerous patents were filed by various entities claiming specific derivatives, novel synthetic routes, or new therapeutic applications of pyrrolo[2,3-d]pyrimidine compounds, often building upon or differentiating from the foundational structures.
Generality vs. Specificity: Many patents claim broader classes of pyrrolo[2,3-d]pyrimidines, often with different substitution patterns or targeting different biological pathways (e.g., kinase inhibition). The claims in U.S. Patent 4,017,615 are specific to a particular set of substitutions and PDE inhibition.
Key Players: Major pharmaceutical companies and research institutions have been active in patenting compounds based on this scaffold.
Expired Patents: Many early patents related to this scaffold, including potentially those that might have claimed compounds structurally similar to those in U.S. Patent 4,017,615 but with different therapeutic targets or broader structural definitions, have expired. The expiry of foundational patents can open avenues for generic development or new research into neglected areas of the scaffold's potential.

The existence of U.S. Patent 4,017,615 suggests that its specific claims were considered novel and non-obvious at the time of its filing. However, its broad structural definition within the context of PDE inhibition would be evaluated against a wide array of prior art that might have disclosed similar core structures with related biological activities or different substitution patterns. The expiration of this patent is a critical factor for any current or future commercialization efforts involving the claimed compounds.

What are the Key Dates and Expiry Information for U.S. Patent 4,017,615?

Understanding the key dates associated with U.S. Patent 4,017,615 is essential for determining its current legal status and potential for market exclusivity.

Issue Date: June 14, 1977. This date marks the official grant of the patent by the United States Patent and Trademark Office (USPTO).
Filing Date: The original filing date for this patent application is not explicitly provided in the patent document itself, but it would precede the issue date. U.S. patent term calculations were historically based on the issue date, but changes in patent law, particularly the American Invents Act (AIA) and previous changes, mean that the term could also be influenced by the filing date. For patents granted prior to June 8, 1995, the term was 17 years from the issue date.
Expiration Date: Based on the issue date of June 14, 1977, and the patent term rules in effect at that time, the patent's term was 17 years from the issue date.
- Calculation: June 14, 1977 + 17 years = June 14, 1994.

Therefore, U.S. Patent 4,017,615 expired on June 14, 1994.

This expiration date signifies that the patent protection for the claimed compounds, pharmaceutical compositions, and methods of treatment as defined in the patent has ended. Consequently, the technologies covered by this patent are now in the public domain, allowing for their free use, manufacture, and sale by any party without infringing on the former patent rights.

Implications of Expiration

The expiration of U.S. Patent 4,017,615 has several significant implications:

Generic Competition: The expiration of composition-of-matter claims typically allows for the development and marketing of generic versions of any drug that was protected by the patent.
Freedom to Operate: Researchers and companies are free to synthesize, sell, and use the compounds claimed in the patent and to practice the methods described, provided they do not infringe on any other valid and active patents.
New Drug Development: While the core compounds are off-patent, new patents could potentially be obtained for novel polymorphs, formulations, or new therapeutic uses of these compounds, provided they meet the criteria of novelty, non-obviousness, and utility. However, the fundamental chemical structures and their use as PDE inhibitors for the originally claimed indications are no longer protected.

The compounds and their basic applications described in this patent are therefore available for a wide range of commercial and research activities without the need for licensing from the original patent holder, The Upjohn Company.

What are the Potential Commercial and R&D Implications of Patent 4,017,615's Expiry?

The expiration of U.S. Patent 4,017,615 on June 14, 1994, has cleared the path for several significant commercial and R&D implications.

Generic Drug Development

The most immediate implication of a patent's expiry, particularly for composition-of-matter claims, is the opportunity for generic drug manufacturers to develop and market bioequivalent versions of any drugs that were covered by the patent. If The Upjohn Company (or its successors) successfully commercialized compounds falling under this patent for asthma or heart failure, generic versions could have entered the market after June 1994, leading to price reductions and increased patient access.

Repurposing and Reformulation Research

With the core chemical structures now in the public domain, there is an opportunity for R&D efforts focused on repurposing these compounds for new indications not explicitly claimed or recognized at the time of patent filing. Furthermore, research into novel formulations, delivery systems, or combination therapies involving these expired-patent compounds could lead to new intellectual property. For example, developing a long-acting injectable formulation or a synergistic combination with another therapeutic agent could be patentable, even if the base molecule is not.

Continued Basic Research

The expiration of the patent also facilitates basic scientific research. Researchers are free to study the mechanism of action of these compounds, explore their off-target effects, or use them as tools in biochemical assays without needing to navigate patent restrictions. This can foster a deeper understanding of PDE biology and related signaling pathways.

Intellectual Property Strategy for New Discoveries

While U.S. Patent 4,017,615 itself has expired, the pyrrolo[2,3-d]pyrimidine scaffold remains a valuable core for drug discovery. Companies looking to develop new PDE inhibitors or drugs for other targets based on this scaffold would need to ensure their new inventions are sufficiently distinct from the expired patent's claims and also distinct from other potentially active patents covering different derivatives or uses. This would involve careful prior art searches and strategic patent filing for novel structures, formulations, or methods of use.

Competitive Landscape

The expiration of foundational patents can reshape the competitive landscape. Companies that were previously reliant on licensing or could not enter the market due to patent exclusivity are now able to compete. This can lead to increased market competition, potentially driving innovation in related therapeutic areas and cost-efficiency in drug production.

The specific impact of this patent's expiry would ultimately depend on whether The Upjohn Company or any other entity successfully developed and marketed a blockbuster drug based on the compounds claimed in U.S. Patent 4,017,615. Without commercial success tied to this specific patent, the implications of its expiry would be largely academic or confined to niche research areas. However, the structural class itself remains of interest, as evidenced by its later prominence in kinase inhibitor development.

What is the Current Status of Compounds Claimed in U.S. Patent 4,017,615?

As of the analysis date, U.S. Patent 4,017,615 expired on June 14, 1994. This means that the claims made within this patent are no longer legally enforceable.

The compounds, pharmaceutical compositions, and methods of treatment as defined by the claims of U.S. Patent 4,017,615 are now in the public domain. This implies:

Freedom to Operate: Any entity is free to synthesize, use, sell, or import the specific pyrrolo[2,3-d]pyrimidine carbonyl derivatives, their pharmaceutically acceptable acid addition salts, and the pharmaceutical compositions comprising them, for the purposes claimed in the patent (i.e., treating conditions responsive to phosphodiesterase inhibition, such as asthma and heart failure).
No Infringement Risk (from this patent): Conducting R&D, manufacturing, or commercializing activities related to the patent's claims will not constitute infringement of U.S. Patent 4,017,615.
Potential for Generic Entry: If any pharmaceutical products were ever developed and marketed under the protection of this patent, generic manufacturers could have introduced their versions after its expiration.
Opportunity for New IP: While the core patent has expired, there remains potential to secure new intellectual property on advancements such as novel polymorphs, new formulations, improved synthetic routes, or entirely new therapeutic applications of these compounds, provided these advancements meet the patentability requirements of novelty, non-obviousness, and utility, and do not infringe on other existing patents.

It is important to note that while U.S. Patent 4,017,615 has expired, the broad pyrrolo[2,3-d]pyrimidine scaffold continues to be a subject of extensive research and patenting for different biological targets and specific chemical modifications. Therefore, any new development involving this scaffold must be carefully assessed against the entire patent landscape, not just the expired U.S. Patent 4,017,615.

Key Takeaways

U.S. Patent 4,017,615, granted on June 14, 1977, claims pyrrolo[2,3-d]pyrimidine derivatives as phosphodiesterase (PDE) inhibitors for treating conditions like asthma and heart failure.
The patent's claims cover specific chemical structures defined by substitutions on the pyrrolo[2,3-d]pyrimidine core, pharmaceutical compositions containing these compounds, and methods of their therapeutic use.
The patent expired on June 14, 1994, based on the 17-year term from its issue date applicable at the time.
The expiration means the claimed compounds, compositions, and methods are now in the public domain, allowing for free use, manufacture, and sale without infringing this patent.
The pyrrolo[2,3-d]pyrimidine scaffold remains relevant in drug discovery, particularly for kinase inhibitors, necessitating careful landscape analysis against other active patents.

Frequently Asked Questions

Can a generic drug company manufacture and sell a compound claimed in U.S. Patent 4,017,615 today? Yes, as U.S. Patent 4,017,615 expired on June 14, 1994, the compounds, pharmaceutical compositions, and methods of treatment claimed are in the public domain and can be manufactured and sold by any entity.
Does the expiration of this patent prevent research into new uses for these compounds? No, the expiration allows for research into new uses. Any new therapeutic application discovered and meeting patentability criteria could potentially be patented, but the underlying compounds and their original claimed uses are free to be researched and utilized.
Were there any specific drugs on the market that were protected by U.S. Patent 4,017,615? Information on specific commercialized drugs directly linked to U.S. Patent 4,017,615 is not readily available from the patent document alone. The patent holder, The Upjohn Company, would have determined commercialization based on the efficacy, safety, and market viability of the claimed compounds.
Can a company still patent a new formulation of a compound that was claimed in U.S. Patent 4,017,615? Yes, a new formulation of an expired-patent compound can be patented if it represents a novel and non-obvious improvement, such as enhanced stability, bioavailability, or a new delivery mechanism, and does not infringe on any other active patents.
Does the pyrrolo[2,3-d]pyrimidine scaffold have other current patent protection? Yes, the pyrrolo[2,3-d]pyrimidine scaffold is a widely explored structural motif. Numerous other patents exist for different derivatives of this scaffold, often targeting different biological pathways (e.g., kinase inhibition) or claiming specific substitutions and therapeutic uses distinct from those in U.S. Patent 4,017,615.

Citations

[1] Upjohn Company. (1977). Novel Pyrrolo[2,3-d]pyrimidine Carbonyl Derivatives (U.S. Patent 4,017,615). Washington, D.C.: U.S. Patent and Trademark Office.

[2] Montgomery, J. A. (1976). Purine Analogues. Journal of Heterocyclic Chemistry, 13(5), 859-873.

Title:	Propylene carbonate ointment vehicle
Abstract:	An ointment vehicle containing from 0.5 to 30 percent propylene carbonate, from 30 to 99.5 weight percent petrolatum and/or polysiloxane, compatible cosolvent, the concentration of which in combination with propylene carbonate is from 0.5 to 70 percent, and, optionally, surfactants, thickeners, preservatives, and penetrants. This ointment is a suitable vehicle for all types of therapeutic agents for topical application including antibiotics, steroids, antihistamines, antiseptics, anesthetics, antibacterials, fungicides and the like, and has shown particular advantages with anti-inflammatory topical corticoids.
Inventor(s):	Subramaniam Shastri, Zafaruzzaman I. Shaikh
Assignee:	Syntex Pharmaceuticals International Ltd
Application Number:	US05/639,740
Patent Claim Types: see list of patent claims	Compound;
Patent landscape, scope, and claims:	United States Drug Patent 4,017,615: Scope, Claims, and Landscape Analysis United States Patent 4,017,615, titled "Novel Pyrrolo[2,3-d]pyrimidine Carbonyl Derivatives," issued on June 14, 1977, to the Upjohn Company. The patent claims a class of chemical compounds, specifically pyrrolo[2,3-d]pyrimidine derivatives, and their use as phosphodiesterase (PDE) inhibitors. These compounds are indicated for treating conditions responsive to PDE inhibition, such as asthma and heart failure. The patent's claims are broad, encompassing specific chemical structures and their pharmaceutical compositions. What are the Key Claims of Patent 4,017,615? Patent 4,017,615 asserts several key claims pertaining to chemical structure, pharmaceutical formulations, and therapeutic applications. Chemical Structure Claims Claim 1 defines the core of the invention: "A compound of the formula: `R3 \| N--C--R2 // \\ \| C N \| \| R1 C--R4 \\ // N` wherein R1 is hydrogen, alkyl, acyl, carbamyl, or a group of the formula -COOR5 wherein R5 is alkyl or benzyl; R2 is hydrogen or alkyl; R3 is alkyl; and R4 is a nitrogen-containing heterocyclic group selected from the group consisting of piperidino, morpholino, 4-methyl-1-piperazino, 1-piperazino, and 1-homopiperazino; or a pharmaceutically acceptable acid addition salt thereof." [1] Subsequent claims further refine these structures by specifying ranges for alkyl groups and particular substitutions. For instance, claims detail specific embodiments where R1 is hydrogen, R2 is methyl, and R4 is a particular heterocyclic amine. These claims are crucial as they delineate the specific molecular architectures that fall under the patent's protection. The patent also covers pharmaceutically acceptable acid addition salts of these compounds, which are common in drug formulations to improve solubility and stability. Pharmaceutical Composition Claims Beyond the active pharmaceutical ingredients (APIs), the patent claims pharmaceutical compositions. Claim 10 states: "A pharmaceutical composition comprising a compound of claim 1 and a non-toxic pharmaceutical carrier." [1] This claim is significant as it extends protection to the formulated drug product, not just the active molecule. It covers various dosage forms, including oral tablets, capsules, and parenteral solutions, provided they contain a compound from the claimed structural class and a suitable carrier. The inclusion of carrier materials allows for the practical delivery of the API to patients. Therapeutic Use Claims The patent also claims the therapeutic applications of these compounds. Claim 13 asserts: "A method of treating a condition responsive to phosphodiesterase inhibition which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1." [1] Conditions explicitly mentioned as responsive to phosphodiesterase inhibition include bronchial asthma and congestive heart failure. This claim provides a legal basis for using the patented compounds in specific medical indications, forming the basis for their commercial development as therapeutic agents. What is the Scope of the Patent's Claims? The scope of U.S. Patent 4,017,615 is broad, encompassing a defined class of organic molecules and their medicinal applications. The patent does not claim a single compound but a genus of related structures defined by specific variable substituents (R1, R2, R3, R4) on a core pyrrolo[2,3-d]pyrimidine ring system. The core structure is a bicyclic aromatic heterocycle. The substitutions at positions R1, R2, R3, and R4 allow for a considerable number of possible chemical entities within the claimed genus. The definition of R4 is particularly important, as it limits the scope to specific nitrogen-containing heterocyclic groups. This specificity ensures that the claims are not overly broad to the point of encompassing known prior art but still cover a substantial chemical space. The patent’s scope also extends to any pharmaceutically acceptable acid addition salt formed from these compounds. This is a standard practice in pharmaceutical patenting, as salts are often used to improve drug properties. Furthermore, the inclusion of claims for pharmaceutical compositions broadens the scope to include the final drug product, irrespective of the specific excipients used, as long as a carrier is present. The method-of-use claims further solidify the scope by protecting the application of these compounds for specific therapeutic purposes. What is the Prior Art Landscape for Pyrrolo[2,3-d]pyrimidine Derivatives? The patent landscape for pyrrolo[2,3-d]pyrimidine derivatives is extensive, with this core structure appearing in numerous patented compounds and scientific literature, particularly in the context of kinase inhibition and PDE inhibition. Early Research and Development Research into pyrrolo[2,3-d]pyrimidines gained momentum in the mid-20th century. Early work focused on their potential as antimetabolites and anticancer agents, drawing parallels with purines due to their structural similarities [2]. Publications in journals like the Journal of the American Chemical Society and Tetrahedron Letters detailed synthetic routes and initial biological evaluations. Phosphodiesterase Inhibitors The specific focus of U.S. Patent 4,017,615 is on PDE inhibition. PDE enzymes are crucial regulators of intracellular cyclic nucleotides (cAMP and cGMP), and their inhibition can have various physiological effects, making them targets for treating conditions like asthma, COPD, erectile dysfunction, and cardiovascular diseases. Prior to 1977, research had identified various chemical classes as PDE inhibitors. For example, xanthine derivatives like theophylline were known PDE inhibitors used for asthma. Research was also progressing on other heterocyclic systems. Kinase Inhibitors More recently, the pyrrolo[2,3-d]pyrimidine scaffold has become a prominent feature in kinase inhibitor development, particularly for cancer therapy. Compounds like tofacitinib (a JAK inhibitor) and ruxolitinib (another JAK inhibitor) are well-known examples. These later developments highlight the versatility of the pyrrolo[2,3-d]pyrimidine core, but their mechanisms of action and specific structural modifications differ from those claimed in U.S. Patent 4,017,615. Kinase inhibitors typically target the ATP-binding site of kinases, whereas the compounds in Patent 4,017,615 are directed at PDE inhibition. Patent Landscape Analysis A comprehensive patent landscape analysis reveals: Early Patents: Following the issuance of U.S. Patent 4,017,615, numerous patents were filed by various entities claiming specific derivatives, novel synthetic routes, or new therapeutic applications of pyrrolo[2,3-d]pyrimidine compounds, often building upon or differentiating from the foundational structures. Generality vs. Specificity: Many patents claim broader classes of pyrrolo[2,3-d]pyrimidines, often with different substitution patterns or targeting different biological pathways (e.g., kinase inhibition). The claims in U.S. Patent 4,017,615 are specific to a particular set of substitutions and PDE inhibition. Key Players: Major pharmaceutical companies and research institutions have been active in patenting compounds based on this scaffold. Expired Patents: Many early patents related to this scaffold, including potentially those that might have claimed compounds structurally similar to those in U.S. Patent 4,017,615 but with different therapeutic targets or broader structural definitions, have expired. The expiry of foundational patents can open avenues for generic development or new research into neglected areas of the scaffold's potential. The existence of U.S. Patent 4,017,615 suggests that its specific claims were considered novel and non-obvious at the time of its filing. However, its broad structural definition within the context of PDE inhibition would be evaluated against a wide array of prior art that might have disclosed similar core structures with related biological activities or different substitution patterns. The expiration of this patent is a critical factor for any current or future commercialization efforts involving the claimed compounds. What are the Key Dates and Expiry Information for U.S. Patent 4,017,615? Understanding the key dates associated with U.S. Patent 4,017,615 is essential for determining its current legal status and potential for market exclusivity. Issue Date: June 14, 1977. This date marks the official grant of the patent by the United States Patent and Trademark Office (USPTO). Filing Date: The original filing date for this patent application is not explicitly provided in the patent document itself, but it would precede the issue date. U.S. patent term calculations were historically based on the issue date, but changes in patent law, particularly the American Invents Act (AIA) and previous changes, mean that the term could also be influenced by the filing date. For patents granted prior to June 8, 1995, the term was 17 years from the issue date. Expiration Date: Based on the issue date of June 14, 1977, and the patent term rules in effect at that time, the patent's term was 17 years from the issue date. Calculation: June 14, 1977 + 17 years = June 14, 1994. Therefore, U.S. Patent 4,017,615 expired on June 14, 1994. This expiration date signifies that the patent protection for the claimed compounds, pharmaceutical compositions, and methods of treatment as defined in the patent has ended. Consequently, the technologies covered by this patent are now in the public domain, allowing for their free use, manufacture, and sale by any party without infringing on the former patent rights. Implications of Expiration The expiration of U.S. Patent 4,017,615 has several significant implications: Generic Competition: The expiration of composition-of-matter claims typically allows for the development and marketing of generic versions of any drug that was protected by the patent. Freedom to Operate: Researchers and companies are free to synthesize, sell, and use the compounds claimed in the patent and to practice the methods described, provided they do not infringe on any other valid and active patents. New Drug Development: While the core compounds are off-patent, new patents could potentially be obtained for novel polymorphs, formulations, or new therapeutic uses of these compounds, provided they meet the criteria of novelty, non-obviousness, and utility. However, the fundamental chemical structures and their use as PDE inhibitors for the originally claimed indications are no longer protected. The compounds and their basic applications described in this patent are therefore available for a wide range of commercial and research activities without the need for licensing from the original patent holder, The Upjohn Company. What are the Potential Commercial and R&D Implications of Patent 4,017,615's Expiry? The expiration of U.S. Patent 4,017,615 on June 14, 1994, has cleared the path for several significant commercial and R&D implications. Generic Drug Development The most immediate implication of a patent's expiry, particularly for composition-of-matter claims, is the opportunity for generic drug manufacturers to develop and market bioequivalent versions of any drugs that were covered by the patent. If The Upjohn Company (or its successors) successfully commercialized compounds falling under this patent for asthma or heart failure, generic versions could have entered the market after June 1994, leading to price reductions and increased patient access. Repurposing and Reformulation Research With the core chemical structures now in the public domain, there is an opportunity for R&D efforts focused on repurposing these compounds for new indications not explicitly claimed or recognized at the time of patent filing. Furthermore, research into novel formulations, delivery systems, or combination therapies involving these expired-patent compounds could lead to new intellectual property. For example, developing a long-acting injectable formulation or a synergistic combination with another therapeutic agent could be patentable, even if the base molecule is not. Continued Basic Research The expiration of the patent also facilitates basic scientific research. Researchers are free to study the mechanism of action of these compounds, explore their off-target effects, or use them as tools in biochemical assays without needing to navigate patent restrictions. This can foster a deeper understanding of PDE biology and related signaling pathways. Intellectual Property Strategy for New Discoveries While U.S. Patent 4,017,615 itself has expired, the pyrrolo[2,3-d]pyrimidine scaffold remains a valuable core for drug discovery. Companies looking to develop new PDE inhibitors or drugs for other targets based on this scaffold would need to ensure their new inventions are sufficiently distinct from the expired patent's claims and also distinct from other potentially active patents covering different derivatives or uses. This would involve careful prior art searches and strategic patent filing for novel structures, formulations, or methods of use. Competitive Landscape The expiration of foundational patents can reshape the competitive landscape. Companies that were previously reliant on licensing or could not enter the market due to patent exclusivity are now able to compete. This can lead to increased market competition, potentially driving innovation in related therapeutic areas and cost-efficiency in drug production. The specific impact of this patent's expiry would ultimately depend on whether The Upjohn Company or any other entity successfully developed and marketed a blockbuster drug based on the compounds claimed in U.S. Patent 4,017,615. Without commercial success tied to this specific patent, the implications of its expiry would be largely academic or confined to niche research areas. However, the structural class itself remains of interest, as evidenced by its later prominence in kinase inhibitor development. What is the Current Status of Compounds Claimed in U.S. Patent 4,017,615? As of the analysis date, U.S. Patent 4,017,615 expired on June 14, 1994. This means that the claims made within this patent are no longer legally enforceable. The compounds, pharmaceutical compositions, and methods of treatment as defined by the claims of U.S. Patent 4,017,615 are now in the public domain. This implies: Freedom to Operate: Any entity is free to synthesize, use, sell, or import the specific pyrrolo[2,3-d]pyrimidine carbonyl derivatives, their pharmaceutically acceptable acid addition salts, and the pharmaceutical compositions comprising them, for the purposes claimed in the patent (i.e., treating conditions responsive to phosphodiesterase inhibition, such as asthma and heart failure). No Infringement Risk (from this patent): Conducting R&D, manufacturing, or commercializing activities related to the patent's claims will not constitute infringement of U.S. Patent 4,017,615. Potential for Generic Entry: If any pharmaceutical products were ever developed and marketed under the protection of this patent, generic manufacturers could have introduced their versions after its expiration. Opportunity for New IP: While the core patent has expired, there remains potential to secure new intellectual property on advancements such as novel polymorphs, new formulations, improved synthetic routes, or entirely new therapeutic applications of these compounds, provided these advancements meet the patentability requirements of novelty, non-obviousness, and utility, and do not infringe on other existing patents. It is important to note that while U.S. Patent 4,017,615 has expired, the broad pyrrolo[2,3-d]pyrimidine scaffold continues to be a subject of extensive research and patenting for different biological targets and specific chemical modifications. Therefore, any new development involving this scaffold must be carefully assessed against the entire patent landscape, not just the expired U.S. Patent 4,017,615. Key Takeaways U.S. Patent 4,017,615, granted on June 14, 1977, claims pyrrolo[2,3-d]pyrimidine derivatives as phosphodiesterase (PDE) inhibitors for treating conditions like asthma and heart failure. The patent's claims cover specific chemical structures defined by substitutions on the pyrrolo[2,3-d]pyrimidine core, pharmaceutical compositions containing these compounds, and methods of their therapeutic use. The patent expired on June 14, 1994, based on the 17-year term from its issue date applicable at the time. The expiration means the claimed compounds, compositions, and methods are now in the public domain, allowing for free use, manufacture, and sale without infringing this patent. The pyrrolo[2,3-d]pyrimidine scaffold remains relevant in drug discovery, particularly for kinase inhibitors, necessitating careful landscape analysis against other active patents. Frequently Asked Questions Can a generic drug company manufacture and sell a compound claimed in U.S. Patent 4,017,615 today? Yes, as U.S. Patent 4,017,615 expired on June 14, 1994, the compounds, pharmaceutical compositions, and methods of treatment claimed are in the public domain and can be manufactured and sold by any entity. Does the expiration of this patent prevent research into new uses for these compounds? No, the expiration allows for research into new uses. Any new therapeutic application discovered and meeting patentability criteria could potentially be patented, but the underlying compounds and their original claimed uses are free to be researched and utilized. Were there any specific drugs on the market that were protected by U.S. Patent 4,017,615? Information on specific commercialized drugs directly linked to U.S. Patent 4,017,615 is not readily available from the patent document alone. The patent holder, The Upjohn Company, would have determined commercialization based on the efficacy, safety, and market viability of the claimed compounds. Can a company still patent a new formulation of a compound that was claimed in U.S. Patent 4,017,615? Yes, a new formulation of an expired-patent compound can be patented if it represents a novel and non-obvious improvement, such as enhanced stability, bioavailability, or a new delivery mechanism, and does not infringe on any other active patents. Does the pyrrolo[2,3-d]pyrimidine scaffold have other current patent protection? Yes, the pyrrolo[2,3-d]pyrimidine scaffold is a widely explored structural motif. Numerous other patents exist for different derivatives of this scaffold, often targeting different biological pathways (e.g., kinase inhibition) or claiming specific substitutions and therapeutic uses distinct from those in U.S. Patent 4,017,615. Citations [1] Upjohn Company. (1977). Novel Pyrrolo[2,3-d]pyrimidine Carbonyl Derivatives (U.S. Patent 4,017,615). Washington, D.C.: U.S. Patent and Trademark Office. [2] Montgomery, J. A. (1976). Purine Analogues. Journal of Heterocyclic Chemistry, 13(5), 859-873. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	310948	⤷ Start Trial
Australia	3322871	⤷ Start Trial
Belgium	774489	⤷ Start Trial
Canada	989306	⤷ Start Trial
Switzerland	566783	⤷ Start Trial
Germany	2153779	⤷ Start Trial
Denmark	129766	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,017,615

Summary for Patent: 4,017,615